Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combigan morning + Ganfort evening versus latanoprost evening for 24-hour intraocular pressure control in high-risk open-angle glaucoma
2013-001634-17Phase 4Completed
- Sponsor
- ASST Santi Paolo e Carlo
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of brimonidine tartrate + timolol maleate, bimatoprost + timolol and latanoprost in open-angle glaucoma (OAG) and pseudoexfoliation glaucoma (PXG) (2 arms), sponsored by ASST Santi Paolo e Carlo. Primary endpoint: Quality of 24-hour intraocular pressure control at 3 and 24 months. Started Jul 2013; status: completed.
02
Drugs
brimonidine tartrate + timolol maleatebimatoprost + timolollatanoprost
03
Conditions
open-angle glaucoma (OAG)pseudoexfoliation glaucoma (PXG)
Beyond the preview
Go deeper on 2013-001634-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001634-17.